ClinConnect ClinConnect Logo
Search / Trial NCT01541267

The Effect of Various Types of the Renin-angiotensin-aldosterone System Blockade on Proteinuria

Launched by MEDICAL UNIVERSITY OF GDANSK · Feb 28, 2012

Trial Information

Current as of June 17, 2025

Completed

Keywords

Aliskiren Eplerenon Telmisartan Direct Renin Inhibitor Ace Inhibitor Mineralocorticoid Inhibitor Proteinuria Chronic Kidney Diseases Renin Angiotensin Aldosterone System

ClinConnect Summary

Pharmacological blockade of the renin-angiotensin-aldosterone system (RAAS) is the main target of therapy to reduces both proteinuria and the rate of decline of the glomerular filtration rate in non-diabetic chronic renal diseases. Despite recent progress, however, there is still no optimal therapy that can stop the progression of these nephropathies. Therefore, it is necessary to optimize such treatment for further improving renal outcome.

The aim of the present study was to compare the effects of three different types of RAAS blockade: (1) mineralocorticoid receptor blocker (MRB) + angio...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • age 18-65 years
  • chronic non-diabetic proteinuric nephropathy
  • chronic kidney disease stage 1-3
  • stable proteinuria above 500 mg/24 hours
  • blood pressure above 125/75 mmHg and below 150/95 mmHg
  • no steroids or other immunosuppressive treatment for a minimum of six months before the study
  • Exclusion Criteria:
  • unstable coronary heart disease
  • decompensated congestive heart failure in the previous 6 months
  • episode of malignant hypertension or stroke in the history
  • diabetes
  • creatinine clearance below 30 ml/min
  • pregnancy

About Medical University Of Gdansk

The Medical University of Gdańsk is a leading institution in healthcare education and research located in Gdańsk, Poland. Renowned for its commitment to advancing medical knowledge and improving patient outcomes, the university actively engages in innovative clinical trials across various medical disciplines. With a focus on multidisciplinary collaboration and state-of-the-art facilities, the Medical University of Gdańsk fosters an environment conducive to groundbreaking research and the development of novel therapeutic interventions. Its dedicated team of researchers, clinicians, and academic professionals is dedicated to enhancing healthcare through rigorous scientific inquiry and community engagement.

Locations

Patients applied

0 patients applied

Trial Officials

Bolesław Rutkowski, Professor

Principal Investigator

Departmen of Nephrology, Transplantation adn Internal Medicine, Medical University of Gdańsk, Poland

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials